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This paper examines the evidence supporting treatments within the renin-angiotensin aldosterone system (RAS), the role
cardioprotection plays within the management of hypertension, considerations around medication adherence, and the role of
the nurse or nurse practitioner in guiding patients to achieve higher hypertension control rates. A large body of data now exists to
supporttheuseofangiotensinreceptorblockers(ARBs)andangiotensin-convertingenzymeinhibitors(ACEIs)whichactonRAS,
in the management of hypertension and their eﬀect on cardiovascular risk reduction. Current evidence suggests that inhibition of
theRASisanimportanttargetforcardioprotection.RASinhibitioncontrolsbloodpressureandalsoreducestarget-organdamage.
This is especially important in populations at high-risk for damage including patients with diabetes and those with chronic kidney
disease. Both ARBs and ACEIs target the RAS oﬀering important reductions in both BP and target organ damage.
1.Introduction
Nurse practitioners and nurses play a key role in the
prevention and management of chronic conditions such as
cardiovascular disease (CVD), diabetes mellitus, and kidney
disease.Despitestridesmadeinitstreatmentandprevention,
CVD remains the leading cause of death worldwide [1].
Myocardial infarction (MI), stroke, and renal failure are
its most common complications. In 2005, CVD was the
underlying cause of 17.5 million deaths, or 30% of all deaths
globally—nearly equal to the entire population of the state
of Florida. MI accounted for 7.6 millions of those deaths and
strokesfor5.7millions[1].IntheUnitedStates,631,636died
from heart disease, the number one cause of death, whereas
137,119 deaths occurred as the result of stroke and 45,344 as
the result of kidney disease [2]. Stroke and kidney diseases
are the third and ninth leading causes of death, respectively.
The morbidity associated with CVD is high as well.
Currently, approximately 24.1 million Americans have been
diagnosed with heart disease, and this condition resulted
in 2.4 million hospital discharges in 2005. Approximately
5.6 million Americans have at one time or another had
a stroke, and in 2005, stroke accounted for 1 million
hospital discharges. About 3.3 million Americans have been
diagnosed with kidney disease [2] .T h ec o s t si nt e r m so f
death, disability, reduced productivity or loss of income, and
healthcare expense are enormous. US healthcare costs for
CVD total more than $149 billions annually, or 17% of all
medical expenditures [3].
Risks associated with CVD include increasing age, male
gender, heredity, hypertension, smoking, high blood choles-
terol, lack of physical activity, diabetes, and obesity [4].
Clearly, age, gender, and heredity cannot be altered. Other
risk factors are modiﬁable, and actions such as smoking
cessation, eating a healthier diet, and getting adequate
exercise can reduce an individual’s risk of developing CVD.
Hypertension is the leading preventable risk factor. It has
shown a continuous, consistent, and independent associa-
tion with the risk of developing CVD [5]. However, control
of hypertension remains less than optimal. Currently, only 1
in 3 patients with hypertension has achieved optimal blood
pressure (BP) control [5].2 Nursing Research and Practice
2.Background
The renin-angiotensin aldosterone system (RAS; Figure 1)
is essential to the regulation of salt and water in the body
[6, 7]. It is the RAS that maintains BP and vascular tone,
primarily through signals from the kidney that are generated
in response to changes in salt and water intake [6–8].
Although most of the RAS is based in the kidneys, there is
tissue RAS as well [6, 7, 9]. The kidney or endocrine RAS is
responsibleforshort-termvolumeandpressureadjustments,
whereasthetissueRASappearstoaﬀectlong-termchangesin
the circulatory system [9, 10].
3. The RAS Cycle
The RAS cycle begins when angiotensinogen is produced in
the liver and excreted. It is converted to angiotensin I by
the enzyme renin, which is produced in the juxtaglomerular
cells of the kidney. Angiotensin-converting enzyme (ACE)
then converts angiotensin I to angiotensin II. Circulating
angiotensin II activates AT1 receptors in a variety of target
tissues, which results in increased water and sodium reab-
sorption, cell proliferation, and changes in vascular tone [7].
The consequences of these eﬀects are an increase in blood
volume and systemic vasoconstriction and a subsequent rise
in BP [7, 8]. It is important to note that angiotensin II can
be generated directly from angiotensinogen through non-
ACE pathways, including cathepsin G, chymase, and ACE-
2-dependent pathways [6, 8, 10]. These alternative pathways
are responsible for persistent production of angiotensin II
during ACE inhibition.
Angiotensin II binds to both AT1 and AT2 receptors.
AT1 upregulates the sympathetic nervous system, increasing
vasoconstriction, aldosterone release, and sodium retention
[6, 8, 10, 11]. Angiotensin II also promotes the production
of free radicals, stimulates plasminogen activator inhibitor-
1 release, and increases tissue factor and vascular cell
adhesion molecule expression [6]. Additionally, angiotensin
II has proatherogenic eﬀects through promotion of vascular
smooth muscle cell proliferation and leukocyte adhesion,
thus playing an important role in the development of
CVD [6, 8]. Angiotensin II also reduces the beneﬁcial
vasodilatory eﬀects of nitric oxide through inhibition of
nitric oxide synthase [10]. However, in binding to the AT2
receptor, angiotensin II mediates apparent beneﬁcial eﬀects
that counterbalance AT1 receptor stimulation [10].
4. The RAS in HypertensionandCVD
Chronic elevation of RAS with subsequent exposure of
tissues to high levels of angiotensin II results in hyperten-
sion, CVD, and target-organ damage. Hypertension creates
stress on the blood vessel walls, giving rise to endothelial
injury and thrombotic and inﬂammatory complications
[12]. The vascular endothelium regulates blood ﬂuidity and
coagulation, vascular growth, inﬂammation, and vascular
tone. These processes are primarily under the control of
the renin-angiotensin and kallikrein-kinin systems [12, 13].
Bradykinin, a potent vasodilator, is degraded by ACE.
In combination with the conversion of angiotensin I to
angiotensin II, the reduction in bradykinin levels by ACE
leads to enhanced vasoconstriction and inhibition of ﬁbri-
nolysis [12, 14, 15] (Figure 2).
The risks of CVD presented by the disruption of vascular
homeostasis in the face of hypertension are increased in
patients with diabetes mellitus. More than 65% of individ-
uals with diabetes die from heart disease or stroke, and their
risk of death from heart disease is 2 to 4 times higher than
that of nondiabetic adults, whereas the risk of death from
stroke is 2.8 times higher [16]. Approximately 73% of adults
with diabetes have hypertension, and diabetes accounts for
44% of new cases of kidney disease each year [16]. It is the
most common reason for kidney transplantation [17].
5.The Role of AngiotensinReceptor Blockers
and ACE Inhibitors: RAS Inhibition
ACEIs and ARBs block the activity of the RAS in diﬀerent
ways. Whereas ACEIs prevent the formation of angiotensin
II by inhibiting ACE, ARBs block the angiotensin II type 1
receptor, thus preventing angiotensin II formed by ACE and
non-ACE pathways from binding to the AT1 receptor. ARBs
also stimulate AT2 receptors [15, 18]. Interestingly, the AT2
receptor antagonizes many of the eﬀects of the AT1 receptor,
suchascellproliferation,andstimulationoftheAT2 receptor
appears to provide protection for certain organs, such as the
brain against ischemia [15].
Long-term use of ACEIs can lead to secondary increases
in angiotensin II and aldosterone through the secondary
(non-ACE) pathways, also known as “ACE escape” [18].
Of the non-ACE pathways, the most important for the
formation of angiotensin II is the chymase pathway [19].
Of signiﬁcant interest, recent data suggest that the chy-
mase pathway is upregulated in diabetic and hypertensive
nephropathy, and thus ACE escape may be more marked in
patients with renal disease [18, 19]. Chymase also has been
found to be upregulated in the coronary vascular and kidney
tissue of patients with diabetes in general [15, 20].
Although the phenomenon of ACE escape represents
a drawback for the ACEI drug class in the treatment
of hypertension, the ARB class is not without its own
shortcomings. Treatment with ARBs may result in rebound
concentrations of renin and angiotensin II by disrupting
the negative feedback loop within the RAS [18]. The renal
RAS has been shown to be separate from the systemic
RAS, and doses of ARBs necessary to achieve adequate
renal tissue concentrations to inhibit intrarenal RAS and
prevent rebound of angiotensin II exceed those necessary to
attain maximal BP-lowering eﬀects [18]. Thus, it has been
suggested that combination therapy with ACEIs and ARBs
may provide the best option for patients with kidney disease,
because some of these patients continue to progress to end-
stage renal disease despite treatment with one or the other
c l a s sa sm o n o t h e r a p y[ 18].
The kidneys are not the only target organs at risk in
patients with hypertension. Hypertension and upregulation
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Figure 2: Important eﬀects of angiotensin II on mechanisms associated with atherosclerosis. Reprinted with permission from Schmieder
et al. [15]
as well, and there is evidence that blockade of the RAS can
reduce damage to these target organs [15]. RAS activation
has been noted to contribute to left ventricular hypertrophy
in patients with primary hypertension independently of and
in addition to the BP load exerted on the left ventricle [15].
The RAS may also play a role in the development of atrial
ﬁbrillation. RAS blockade by ARBs in animals has been
shown to slow conductivity and to prevent left atrial dilation
and ﬁbrosis, suggesting that RAS blockade may be eﬀective
as a preventive and therapeutic strategy for atrial ﬁbrillation
[15]. Stroke is another important CVD complication, and
hypertension contributes substantially to its risk. Good BP
control is the most eﬀective method of reducing this risk.
However, meta-analyses indicate that ARBs provide beneﬁt4 Nursing Research and Practice
instrokeriskreductionthatgobeyondBPcontrol[15].Cere-
bralAT2 receptorsexertneuroprotectiveeﬀectsinresponseto
ischemic neuronal damage. Therefore, stimulation of these
r e c e p t o r sb yA R B sm a yp r o v em o r ee ﬀective in stroke man-
agement than therapy with ACEIs [15, 21]. Atherosclerosis
contributes to risk of coronary and cerebrovascular events.
The binding of angiotensin II to the AT1 receptors appears
to be central to the atherosclerotic cascade, implicating the
RAS in endothelial dysfunction and the development of
atherosclerosis. Evidence suggests that both ACEIs and ARBs
improve endothelial function [15]. Finally, RAS blockade
may reduce insulin resistance, which is characteristic of both
the metabolic syndrome and type 2 diabetes mellitus. Data
indicatethatbothACEIsandARBsmayreducethefrequency
of new-onset type 2 diabetes in hypertensive patients, in
contrast to β-blockers and diuretics, which do not [15].
6. The Present Paper
A large body of data now exists to support the use of
angiotensin receptor blockers (ARBs) and ACE inhibitors
(ACEIs) in the management of hypertension [15, 17, 22, 23].
7. Trials of ACEIs
The Heart Outcomes Prevention Evaluation (HOPE) trial
investigated the eﬀects of the ACEI ramipril on cardiovas-
cular (CV) events in 9,297 patients who had diabetes or
evidence of CVD (coronary, cerebrovascular, or peripheral
artery disease) and were therefore considered at high risk,
but who did not have left ventricular dysfunction or heart
failure (HF) [23]. Patients were randomly assigned to receive
either ramipril 10mg once daily or matching placebo for 5
years. The primary endpoint was a composite of MI, stroke,
or CV-related death.
The primary endpoint was reached by 14.1% (n = 651)
of those receiving ramipril and 17.8% (n = 826) of those in
the placebo group (P<.001). The relative risk was 0.78, and
the upper bound of the 95% conﬁdence interval (CI) of 0.70
to 0.86 includes at least a relative risk reduction of 14% [23].
Statistically signiﬁcant reductions were also found for death
fromCVcauses(6.1%forramipril,8.1%forplacebo;relative
risk, 0.74; P<.001), MI (9.9% versus 12.3%, resp.; relative
risk, 0.80; P<.001), stroke (3.4% versus 4.9%, resp.; relative
risk, 0.68; P<.001), and death from any cause (10.4% versus
12.2%; relative risk, 0.84; P<.005) [23]. Complications
related to diabetes were signiﬁcantly reduced as well (6.4%
versus 7.6%, resp.; relative risk, 0.84; P<.03).
The ﬁndings of HOPE provided evidence-based support
that ramipril is beneﬁcial in a broad range of patients
considered to be at high risk for CV events. Ramipril
lowered the combined primary endpoint in the total patient
population by 22%. The magnitude of beneﬁt with ramipril
wasatleastasgreatasthatachievedwithagentsasβ-blockers,
aspirin, and lipid-lowering agents for secondary prevention
over 4 years of treatment [23].
In the subgroup of patients with diabetes (38.5%; n =
3,577), the risk of the combined primary endpoint was
signiﬁcantly reduced by 25% (95% CI, 12–36; P = .0004),
and progression to overt nephropathy was reduced by 24%
(95% CI, 3–40; P = .027) [23, 24].
EUROPA (European trial On reduction of cardiac events
withPerindoprilinpatientswithstableArterydisease)exam-
ined the use of another ACEI, perindopril, in 13,655 patients
with stable coronary artery disease, including 64% with a
previous MI, 61% with angiographic evidence of coronary
artery disease, 55% with coronary revascularization, and 5%
whoseonlyevidenceofcoronaryarterydiseasewasapositive
stress test. After a preliminary run-in period of 5 weeks,
during which all patients received perindopril, patients were
randomized to perindopril 8mg once daily (n = 6,110)
or matching placebo (n = 6,108). The primary outcome
measure was time to ﬁrst occurrence of CV death, MI, or
cardiac arrest [25]. Patients also received other agents known
to reduce CV risk, including β-blockers, aspirin, and lipid-
lowering agents [25].
Themeanfollow-upwas4.2years.Theprimaryendpoint
was experienced by 8% of those receiving perindopril and
10% of those on placebo, for a 20% relative risk reduction
in favor of perindopril (95% CI, 9–29; P = .0003). The
investigators concluded that in patients with stable coronary
heart disease and without apparent HF, 50 patients would
need to be treated with perindopril for 4 years to prevent one
major CV event [25].
The Prevention of Events with Angiotensin Converting
Enzyme Inhibition (PEACE) trial investigated an ACEI,
trandolapril, in 8,290 patients with stable coronary artery
disease. Patients were randomized to either trandolapril
4mg per day or matching placebo; 72% of patients had
previously undergone coronary revascularization and 70%
received lipid-lowering drugs during the trial period [26].
The primary endpoint was death from CV causes, MI, or
coronary revascularization. Over 4.8 years, this outcome
occurred in 21.9% of those receiving trandolapril and 22.5
of those receiving placebo (hazard ratio, 0.96; 95% CI, 0.88–
1.06; P = .43). This study indicated that the addition of an
ACEI provides no further beneﬁt in terms of death from CV
causes, MI, or coronary revascularization [26].
8. Trials of ARBs
ARBs have also ﬁgured prominently in recent clinical trials.
The Candesartan in Heart Failure: Assessment of Reduction
in Mortality and Morbidity (CHARM)-Alternative study
looked at candesartan therapy in patients with chronic
HF and reduced left-ventricular systolic function who
were intolerant to ACEIs. A total of 2,028 patients with
symptomatic HF and a left-ventricular ejection fraction of
40% or less were randomized to receive a targeted dose
of candesartan 32mg once daily or matching placebo. The
primary endpoint was the composite of CV death or hospital
admission for chronic HF [27].
Over a mean follow-up of 33.7 months, 33% of the
patients receiving candesartan and 40% of those receiv-
ing placebo experienced the primary endpoint (hazard
ratio, 0.77; 95% CI, 0.67–0.89; P = .0004), resulting inNursing Research and Practice 5
a 23% relative risk reduction with candesartan. Impor-
tantly, permanent discontinuation of study drug was sim-
ilar in the candesartan (30%) and placebo (29%) groups
[27].
Valsartan also was investigated in patients with chronic
HF. A total of 5,010 chronic HF patients already receiving
pharmacologic therapy considered optimal by their physi-
cians (93% were on an ACEI at baseline) were randomly
assignedtovalsartan160mgtwicedailyormatchingplacebo.
The primary endpoints were mortality and the combined
endpoint of mortality and morbidity, deﬁned as cardiac
arrest with resuscitation, hospitalization for HF, or receipt
of inotropic or vasodilator therapy for 4 hours or more
[28].
Although overall mortality was similar in both groups,
the combined endpoint was 13.2% lower in the valsartan
group than with placebo (relative risk, 0.87; 97.5% CI, 0.77–
0.97; P = .009). This latter result was primarily driven
by a lower incidence of patients hospitalized for HF in
the valsartan group compared with placebo (13.8% versus
182%, resp.; P<.001). Treatment with valsartan was also
associated with improvement in New York Heart Association
class, ejection fraction, signs and symptoms of HF, and
quality of life as compared with placebo (P<.01). Thus,
valsartan proved to be valuable when added to prescribed
therapy in patients with HF. However, a post hoc analysis of
a subgroup of patients receiving a combination of valsartan,
an ACEI, and a β-blocker had an increase in mortality and
morbidity, suggesting that not all combinations improve
patient outcomes [28].
The Ongoing Telmisartan Alone and in Combination
with Ramipril Global Endpoint Trial (ONTARGET) was
conducted in patients with vascular disease or high-risk
diabetes without HF to determine if the ARB, telmisartan,
would be as eﬀective as the ACEI, ramipril; and whether a
combination of both agents would be superior to ramipril
alone. Patients were randomized to ramipril 10mg daily
(n = 8,576), telmisartan 80mg daily (n = 8,542), or a
combination of both agents (n = 8,502). The primary
composite endpoint was death from CV causes, MI, stroke,
or hospitalization for HF [27].
At a median follow-up of 56 months, the primary
endpoint was reached by 16.5% of those in the ramipril
group and 16.7% in the telmisartan group (relative risk,
1.01; 95% CI, 0.94–1.09). The telmisartan group had lower
incidence of cough and angioedema and a higher inci-
dence of hypotensive symptoms associated with permanent
discontinuation of study medication compared with the
ramipril group. The investigators concluded that telmisartan
was as eﬀective as ramipril in reducing the risk for CV
death/MI/stroke and hospitalization for HF in this high-risk
patient population [27].
9. Trials of Combination Therapy with
ACEIsandARBs
Because ACEIs and ARBs inhibit the RAS in diﬀerent
and potentially complementary ways, it was thought that
combination therapy with these 2 drug classes might prove
beneﬁcial in preventing or mitigating target-organ damage
in patients with hypertension. The CHARM-Added study
evaluated the eﬃcacy of candesartan in patients with chronic
HF and reduced left-ventricular systolic function. A total
of 2,548 patients were randomized to either a targeted dose
of 32mg of candesartan once daily or placebo in addition
to concurrent ACEI therapy. The primary outcome was the
composite of CV death or admission to hospital for chronic
HF [29].
Over a median follow-up of 41 months, 38% of patients
receiving candesartan and 42% receiving placebo experi-
enced a primary outcome event. The hazard ratio was
0.85 (95% CI, 0.75–0.96; P = .011), signiﬁcantly favoring
candesartan versus placebo. The annual event rates were
14.1% in the candesartan group and 16.6% in the placebo
group [29]. CHARM-Added showed that in patients with
chronic HF and a low left-ventricular ejection fraction, the
addition of candesartan to an ACEI led to further reductions
intheriskofCV-relatedmortalityandhospitaladmissionfor
chronic HF [29].
In the Valsartan in Acute Myocardial Infarction Trial
(VALIANT), the eﬃcacy of monotherapy with valsartan,
captopril, or the combination of the 2 was explored in
patients who had experienced an acute MI. Within 0.5
to 10 days after the event, patients were randomized to
valsartan (4,909 patients), captopril (4,909 patients), or the
combination (4,885 patients). The primary study outcome
was death from any cause [30].
At a median follow-up of 24.7 months, 19.9% of patients
receiving valsartan, 19.5% of patients receiving captopril,
and 19.3% of patients receiving combination therapy had
died. These diﬀerences were not signiﬁcant, and valsartan
was found to be noninferior to captopril (P = .004), but
no beneﬁt was found for the combination therapy for this
endpoint. However, drug-related adverse eﬀects were more
common with the combination of valsartan and captopril
than in either monotherapy group [30].
ONTARGET found that the combination of telmisartan
plus ramipril was not superior to ramipril alone. The
primary outcome of CV death, MI, stroke, or hospitalization
for HF occurred in 16.3% of patients receiving combination
therapy, as compared with 16.5% in those receiving ramipril
(relative risk, 0.99; 95% CI, 0.92–1.07). The combination
resulted in signiﬁcantly higher incidence of hypotensive
symptoms, syncope, and renal dysfunction compared with
ramipril alone [27].
The results of ONTARGET suggest that combining 2
distinct classes of agents that inhibit the RAS at diﬀerent sites
does not improve patient outcomes in a broad spectrum of
high-risk subjects without HF. It corroborates the ﬁndings
of VALIANT and is in contrast to the ﬁndings of CHARM-
Added. However, it must also be noted that the ONTARGET
patient population and that of VALIANT diﬀer fundamen-
tally, because the latter trial was conducted in patients
w h oh a de x p e r i e n c e da na c u t eM Ia n dh a ds i g n so fH F ,
radiographicevidenceofleftventricularsystolicdysfunction,
or both.6 Nursing Research and Practice
10. Adherence withRAS Agents
While the use of RAS agents has shown some signiﬁcant ben-
eﬁtwithin controlledstudies, therecontinues to bea struggle
with many patients taking their prescribed medication to
achieve maximum outcomes. There are no recent studies
speciﬁc to nurses and their role within the management of
RAS agents relative to a patient’s adherence to medications;
however, several factors can be seen through other studies. A
recent study within hypertension has shown that medication
adherence was signiﬁcantly associated with systolic blood
pressure (r = .253, P<.04), thus, prompting the need for
strict adherence to prescribed regimens [31]. This adherence
can be increased with a long-term intervention from health
professionals as seen in the VALIDATE Study; however,
when such an intervention stops, adherence declines as well
[32]. This decline points out that a healthcare provider’s
intervention is only one component in increasing adherence.
In a 2005 HealthStyles survey of 1432 individuals who
received prescriptions for antihypertensive medications, 407
(28.4%) reported having diﬃculty taking their medication.
“Not remembering” was the most common reason reported
(32.4%), but cost (22.6%), having no insurance (22.4%),
side eﬀects (12.5%), and not thinking there is any need
(9.3%) were also important indicators. Additionally younger
age, lower income, having mental function impairment, and
having had a blood pressure check more than 6 months
earlier were factors signiﬁcantly associated with nonadher-
ence. While utilizing the right medications to decrease the
risk of cardiovascular disease is vital, alleviating barriers
to medication adherence should be a major goal within
management [33].
11. Discussion
ARBs are a proven option in patients with hypertension,
particularly those who are at risk for target-organ damage,
such as those with diabetes or evidence of CVD. Evidence
from clinical trials demonstrates that these agents provide
good control of hypertension and reduce CV risk. To this
end, some ACEIs and ARBs have received FDA-approved
indications to reduce CV risk. Adverse eﬀects associated
with use of ACEIs include cough, rash, taste disturbance,
and angioedema. Cough, angioedema, taste disturbance,
and rash occur less frequently with ARBs than with ACEIs.
However, hypotension is more common with ARBs than
ACEIs [30].
The side-eﬀe c tp r o ﬁ l eo fA R B sm a yl e a dt ob e t t e r
adherence on the part of patients. Adherence is notoriously
poor with hypertension. Nonadherence to hypertension
therapy is inﬂuenced by misunderstanding of the condition
or treatment, denial of illness because of lack of symp-
toms, lack of patient involvement in the care plan, or
unexpected adverse eﬀects of medications. Many of these
contribute to the 34% of hypertension patients who are not
adequately controlled with their current treatment regimen
[5].
However, adherence is an area in which nurses and nurse
practitioners can have a positive impact. Patients must be
motivated to take their medication as prescribed, and to
do so, they must understand the importance of doing so.
Patient motivation is enhanced through education, positive
experiences with the healthcare system, and trusting in
the nurses and nurse practitioners who oversee medical
care. Empathy by all healthcare professionals is a powerful
motivator [5]. Patients must agree on BP goals, and the
cost of medications and the complexity of the regimen must
be taken into account. Patients must also be clear about
their responsibility to adhere to the regimen and must make
sensible lifestyle changes [5].
12. Conclusions
Inhibition of the RAS is an important target for cardio-
protection. RAS inhibition not only controls BP, but it also
reduces target-organ damage. This is especially important in
populations at high risk for such damage, such as diabetics
andthosewithchronickidneydisease.BothARBsandACEIs
eﬀectively control the RAS, oﬀering important reductions in
both BP and target-organ damage.
13.Relevance toClinicalPractice
Cardiovascular protection is a key element in the overall
management of hypertension. Since the risk of CVD doubles
with each increment of 20/10mmHg, there should be some
care given to selecting the right agent for an individual [5].
Due to the overwhelming positive data on the inhibition
of the RAS, selection of an agent in these classes should
be considered. However, other factors such as patient co-
morbidities, adherence, and risk for potential adverse drug
events must also be considered when selecting an agent.
Depending on the patient’s needs, the use of ARBs or
ACEIs can be used to eﬀectively inhibit the RAS, oﬀering
important reductions in both BP and target-organ damage.
Before selecting which agent to use to manage hypertension,
consideration should be given to both classes’ agents with
respect to their FDA-approved indications.
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